While this observation again points to a model in which BCRP+ tumor cells are positively selected in this organ (Fig. 6D), the reexpression of BCRP in BCRP-shRNA1 brain tumors technically prevents us from studying the response to doxorubicin in this setting. This evidence concerns the gene ABCG2 and neoplasm.